Abbott Laboratories received U.S. Food and Drug Administration (FDA) approval this week to market adalimumab (Humira), previously known as D2E7. The drug was approved for the treatment of moderately to severely active rheumatoid arthritis (RA) in patients who have had insufficient response to one or more traditional disease-modifying antirheumatic drugs (DMARDs).
Adalimumab is approved for use alone or in combination with traditional DMARDs. “We’re pleased to receive the approval of HUMIRA earlier than anticipated,” said Miles D. White, chairman and chief executive officer, Abbott Laboratories. “The approval of HUMIRA is not only a milestone for Abbott, more importantly it is an example of the positive impact pharmaceutical innovation can have for people living with chronic and debilitating conditions like RA.”
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!